NEW YORK, Aug. 13 (GenomeWeb News) - Lynx Therapeutics of Hayward, Calif., reported increased revenues and slashed its net loss nearly in half, but with $3 million in cash and cash equivalents, including restricted cash, on hand, the company is "considering various other options, including additional equity financing," Kevin Corcoran, the company president and CEO said in a statement today.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.